Sheet 1	of 1								
EORM PTO 1449 (modified)						Attorney Docket - P67900US1			
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					Application No 10/513,962				
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)					Applicant - Forssmann, et al.				
					Filing Date - February 8, 2005				
RADEMARI			U.S. PATENT D	OCUMENTS	1		1 0010	, 2005	
Examiner ¹	Ref.#	·	Document No.			Date	Pa	tentee/Applicant	
		·		1				· · · · · · · · · · · · · · · · · · ·	
		· · · · · · · · · · · · · · · · · · ·						 	
		<u> </u>	FOOTION DATENT		L	<u> </u>			
		Country	FOREIGN PATENT Document No.					D-11	
/S.G./		EP	1 167 527	Translation		Date 04/02/02		Patentee	
		<u>Cr</u>	1 107 527			01/02/02			
				0					
					0			·	
	-					ļ. 			
				<u> </u>					
		L			0	<u> </u>			
		<u> </u>	NON-PATENT D	OCUMENTS					
Examiner	Ref. #	Author (in CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages)							
/S.G./		Detheux, M., et al., "Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties," The Journal of Experimental Medicine, vol. 192, no. 10, November 20, 2000, pgs. 1501-1508, [XP002241991].							
/S.G./		Muench, J., et al., "Hemofiltrate CC chemokine 1(9-74) causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages," Antimicrobial Agents and Chemotherapy, vol. 46, no. 4, April 2002, pgs. 982-990, [XP002241992].							
/S.G./		Teran, L. M., "CCL Chemokines and asthma," Immunology Today, vol. 21, no. 5, May 2000, pgs. 235-242, [XP004198513].							
Examiner Signature /Satyanarayan Gudibande/							Date Considered 08/15/2007		

[†]Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.